Here you can find all of our investor related information including press releases, presentations, financial reports and prospectuses.
Additionally, we have included information about the share, governance, financial targets and the calendar.
If you have further questions, please contact our IR contact.
If you are interested in receiving our press releases and reports, please click on “Subscribe”.
Immunovia AB published the company’s Interim Report January–September 2021 on Thursday, November 11, 2021, at 4.00 p.m. CET.
Place: Immunovia website
Immunovia CEO Patrik Dahlen presents the company at Vator Securities Healthcare Innovation Summit, October 12, 2021
IMMray™ PanCan-d is provided as a laboratory developed test (LDT) exclusively by Immunovia, Inc. in the US.
The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.
Ticker on Nasdaq Stockholm: IMMNOV
The shares are registered by Euroclear Sweden.